UNSPSC 51143704: Amitriptyline/perphenazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.

UNSPSC 51143704 Amitriptyline/perphenazine is a Commodity code that encompasses prescription pharmaceuticals and related drug products procured by state and local health agencies, though recent opportunities tagged under this code show limited direct alignment with the code's nominal scope. State and local governments buying under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances representing multiple jurisdictions. The work actually being solicited spans generic multi-source pharmaceuticals supplied through authorized wholesalers, direct-to-manufacturer prescription programs under pharmacy benefit initiatives, and specialized health products including naloxone and drug deactivation systems. Issuing bodies range from single-county health authorities to multi-state cooperative purchasing vehicles; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission are repeat procurers signaling statewide or regional consolidation of pharmaceutical purchasing.

Recent activity concentrates in Florida and the Upper Midwest, with the Texas Health and Human Services Commission conducting exploratory market research. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to supply through three authorized wholesalers and meet cGMP and DSCSA compliance; the contract term is two years with optional extensions, and the procurement evaluates price competitiveness at 75 percent weight. Seminole County, Florida posted an IFB on June 30, 2026, for naloxone and safe drug deactivation systems (1,900 units and 800 systems annually, respectively) due July 26, 2023, with quarterly deliveries to the county community health building and an initial two-year term plus optional one-year renewal. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, positioning the state to design a formal procurement strategy before issuing a subsequent RFP.